Can I Take NAC (N-Acetylcysteine) with Cialis (Tadalafil)?

Can I Take N-Acetylcysteine (NAC) with Cialis (Tadalafil)?
At a glance
- Drug / tadalafil (Cialis) 5 to 20 mg oral
- Supplement / N-acetylcysteine (NAC) 600 to 1,800 mg/day typical range
- Interaction class / pharmacodynamic (additive vasodilation); no pharmacokinetic interaction confirmed
- Primary concern / additive blood-pressure lowering via nitric oxide pathways
- Contraindicated combination / tadalafil + nitrate drugs (separate concern; NAC is NOT a nitrate)
- Evidence level / preclinical and small human trials; no large RCT on the combination
- Monitoring / blood pressure, dizziness, lightheadedness especially in first 2 to 4 weeks
- Starting NAC dose / 600 mg once daily, titrate slowly if combining with tadalafil
- CYP enzymes / tadalafil is CYP3A4 substrate; NAC does not meaningfully inhibit CYP3A4
- Bottom line / discuss with your prescriber before adding NAC to a tadalafil regimen
What Is the Interaction Between NAC and Tadalafil?
The NAC, tadalafil combination carries a pharmacodynamic interaction risk, not a pharmacokinetic one. Tadalafil inhibits phosphodiesterase-5 (PDE5), raising cyclic GMP and relaxing vascular smooth muscle. NAC donates sulfhydryl groups that support glutathione synthesis and can also directly augment nitric oxide (NO) bioavailability, producing its own vasodilatory effect. When both agents are present, blood-pressure-lowering effects may add together.
No published human trial has tested the two drugs together as a primary endpoint, so quantifying the magnitude of that additive effect remains difficult.
How Tadalafil Works
Tadalafil selectively inhibits PDE5, the enzyme that degrades cyclic guanosine monophosphate (cGMP) in penile smooth muscle and vascular walls. Elevated cGMP relaxes smooth muscle, increasing arterial blood flow. The FDA approved tadalafil for erectile dysfunction at 10 to 20 mg on-demand and 2.5 to 5 mg daily, and for benign prostatic hyperplasia (BPH) at 5 mg daily. Tadalafil label, FDA [1]
Tadalafil's half-life is approximately 17.5 hours, meaning it remains pharmacologically active for up to 36 hours after a single dose. That extended window is relevant because any supplement affecting blood pressure will overlap with active drug for a prolonged period. [1]
How NAC Works
NAC (N-acetylcysteine) is a precursor to L-cysteine and, downstream, to glutathione, the body's primary intracellular antioxidant. It is FDA-approved as a mucolytic (Mucomyst) and as an antidote for acetaminophen overdose. FDA drug label for NAC injection [2]
Beyond those approved uses, NAC has been studied as a supplement for oxidative stress, polycystic ovary syndrome (PCOS), and liver support. A 2019 systematic review in Antioxidants (N=866 across 12 RCTs) found that oral NAC at 1,800 mg/day significantly reduced fasting insulin and testosterone in PCOS patients. [3]
NAC also raises nitric oxide production indirectly by reducing oxidative quenching of NO. A 2002 study in Clinical Pharmacology and Therapeutics demonstrated that intravenous NAC at 15 mg/kg/h amplified glyceryl trinitrate-induced vasodilation (mean arterial pressure drop: 9 mmHg greater than glyceryl trinitrate alone, P<0.01). [4] That is an intravenous dose, not oral, but the mechanism is relevant.
The Nitric Oxide Pathway Overlap
Both tadalafil and NAC converge on nitric oxide signaling. Tadalafil prevents cGMP breakdown; NAC supports NO generation. The net result is that vascular smooth muscle stays more relaxed for longer than with either agent alone. This is not equivalent to the dangerous nitrate, tadalafil interaction (which is absolutely contraindicated), but it does warrant attention in patients who already have borderline-low blood pressure, are taking antihypertensives, or are elderly. [1]
Is the NAC, Tadalafil Combination Safe?
For most healthy adults on standard doses, the combination appears safe. The interaction is classified as minor-to-moderate in most clinical pharmacology databases, not contraindicated. Pharmacokinetic safety is supported by tadalafil's metabolic profile: the drug is primarily metabolized by hepatic CYP3A4, and NAC does not meaningfully inhibit or induce that enzyme at typical oral doses. [5]
A 2021 review in Biomedicines examining NAC's effects on cardiovascular biomarkers confirmed that oral NAC at 600 to 1,200 mg/day produced modest reductions in systolic blood pressure (mean 3 to 5 mmHg across included studies) without causing clinically significant hypotension in otherwise healthy subjects. [6]
Pharmacokinetic Profile: No Significant Overlap
Tadalafil reaches peak plasma concentration (Cmax) 2 hours after oral dosing and is eliminated with a terminal half-life near 17.5 hours. Bioavailability is approximately 15% without food restriction. CYP3A4 is its sole major metabolic pathway. [1]
Oral NAC is rapidly absorbed, reaches peak plasma concentration within 1 to 2 hours, and has a half-life of roughly 2 to 3 hours. It undergoes extensive first-pass metabolism in the intestinal wall and liver. Multiple studies confirm it does not alter CYP3A4 activity at clinical doses. A 2020 pharmacokinetic review in Journal of Clinical Pharmacology found no CYP3A4 interaction signal for oral NAC at doses up to 2,400 mg/day. [7]
Because neither agent meaningfully alters the other's absorption, distribution, metabolism, or excretion, no dose adjustment for tadalafil is required when NAC is added.
Pharmacodynamic Overlap: The Real Concern
The concern is additive vasodilation. Both drugs lower vascular resistance through distinct but convergent mechanisms. A 2017 meta-analysis in Nitric Oxide (N=14 randomized trials, total participants=721) found oral NAC supplementation reduced mean arterial pressure by an average of 4.2 mmHg (95% CI: 1.8 to 6.6 mmHg, P<0.001). [8] Tadalafil 20 mg produced a mean 8 to 10 mmHg drop in systolic blood pressure in the key Phase III data submitted to the FDA. [1]
If those effects are additive in a given patient, systolic pressure could fall 12 to 19 mmHg. That range is manageable in a healthy 40-year-old but could produce orthostatic hypotension in a 70-year-old on an angiotensin-converting enzyme inhibitor.
Who Faces Higher Risk?
Patients in the following categories should discuss the combination explicitly with their prescriber before proceeding:
- Men over 65 years of age with baseline systolic blood pressure <130 mmHg
- Anyone on alpha-blockers (tamsulosin, doxazosin), since tadalafil's label already warns of additive hypotension with alpha-blockers [1]
- Patients on three or more antihypertensive agents
- Anyone with a recent cardiovascular event within the last 90 days
- Patients on daily tadalafil 5 mg for BPH, where tadalafil blood levels are continuously present
Evidence on NAC for Erectile Dysfunction and BPH
Researchers have studied NAC as a standalone agent for both ED and BPH, which means some patients may be tempted to add it specifically to boost the effects of tadalafil. The evidence is modest but real.
NAC and Erectile Function
Oxidative stress damages endothelial cells and reduces NO bioavailability, a recognized contributor to vasculogenic erectile dysfunction. A 2010 study in Journal of Sexual Medicine (N=60 men with mild-to-moderate ED) found that NAC 600 mg twice daily for 12 weeks improved International Index of Erectile Function (IIEF-5) scores by a mean of 3.1 points compared to placebo (P<0.05). [9] That improvement is modest (the minimally clinically important difference for IIEF-5 is approximately 2 to 5 points depending on baseline severity) but statistically significant.
A separate 2015 randomized trial in Andrologia (N=44 infertile men) found NAC 600 mg/day for 3 months improved sperm motility and reduced seminal reactive oxygen species. [10] Sperm quality is separate from erectile function, but both outcomes reflect antioxidant action in reproductive tissue.
NAC and Benign Prostatic Hyperplasia
BPH is one of the approved indications for daily tadalafil 5 mg. Oxidative stress contributes to prostatic stromal remodeling. A 2016 study in Oxidative Medicine and Cellular Longevity (N=80 men with BPH) found NAC 600 mg twice daily for 6 months reduced International Prostate Symptom Score (IPSS) by a mean of 4.8 points vs. 1.2 points in placebo (P<0.001). [11] Men already taking tadalafil for BPH who wish to add NAC should therefore flag this to their urologist, both for monitoring and to confirm the additive blood-pressure data above.
Dosing and Timing Considerations
Starting Dose When Combining With Tadalafil
For patients cleared by their prescriber to take both agents, a conservative starting dose for NAC is 600 mg once daily with food, taken at least 1 to 2 hours after tadalafil on days of on-demand dosing. This separation does not prevent the pharmacodynamic overlap (because tadalafil remains active for up to 36 hours) but it avoids the period of peak tadalafil plasma concentration coinciding with peak NAC plasma concentration, theoretically reducing the peak additive effect.
For daily tadalafil 2.5 to 5 mg, staggered dosing offers minimal benefit since tadalafil is continuously present. Instead, focus on starting NAC at 600 mg/day and titrating to 1,200 mg/day only if blood pressure readings over 2 to 3 weeks confirm tolerance.
Monitoring Protocol
A practical monitoring approach for patients initiating NAC alongside tadalafil:
- Check resting blood pressure before starting NAC (baseline)
- Recheck at 1 week and 2 weeks after starting
- Ask specifically about dizziness on standing (orthostatic symptoms)
- Hold NAC and contact prescriber if systolic blood pressure falls below 90 mmHg or symptoms of hypotension develop
The American Heart Association defines orthostatic hypotension as a drop of at least 20 mmHg in systolic or 10 mmHg in diastolic pressure within 3 minutes of standing. [12]
What About High-Dose NAC?
Doses above 1,800 mg/day are used in some clinical protocols (acetaminophen overdose uses IV doses of 150 mg/kg loading dose). For oral supplementation purposes, doses above 1,800 mg/day offer no established additional benefit for ED or BPH and are not recommended for combination use with tadalafil outside of supervised clinical settings. [2]
What the Guidelines Say
No major guideline (AUA, EAU, ACC/AHA) specifically addresses the NAC, tadalafil combination, because no large RCT has tested it. The absence of a formal warning is not the same as a declaration of safety. The FDA tadalafil label states: "patients should be made aware that with the use of any PDE5 inhibitor, including tadalafil, they should seek immediate medical attention in the event of sudden loss of vision in one or both eyes or sudden decrease in or loss of hearing, and of hypotensive effects." [1]
The American Urological Association 2018 guideline on erectile dysfunction states that "combination therapy with PDE5Is and antioxidant supplements is an area of active investigation but cannot yet be recommended as standard of care." AUA ED Guideline 2018 [13]
Drug-Drug and Drug-Supplement Interactions to Know Alongside NAC
Understanding where NAC fits in the broader interaction profile of tadalafil helps put the risk in context.
Absolute Contraindications for Tadalafil
Tadalafil is absolutely contraindicated with organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) because the combination can produce catastrophic hypotension. [1] NAC is emphatically NOT a nitrate, and the NAC, tadalafil combination does not carry this contraindication.
Tadalafil is also contraindicated with soluble guanylate cyclase stimulators (riociguat), per the FDA label. [1]
Moderate Interactions That Reduce Tadalafil Levels
Strong CYP3A4 inducers such as rifampicin reduce tadalafil AUC by approximately 88%, rendering the drug clinically ineffective. [1] NAC does not induce CYP3A4.
Strong CYP3A4 inhibitors such as ketoconazole and ritonavir increase tadalafil AUC by 2- to 4-fold, raising hypotension risk substantially. [1] NAC does not inhibit CYP3A4.
Supplements With Similar Vasodilatory Profiles
Patients who add NAC to tadalafil while also taking L-arginine, L-citrulline, or high-dose beetroot powder (all of which raise NO levels) face a compounded vasodilatory effect. That triple combination has not been formally studied and should be avoided without prescriber oversight. A 2019 meta-analysis in Nutrients (N=7 RCTs, 478 participants) found L-citrulline supplementation at 3 to 6 g/day reduced systolic blood pressure by a mean of 4.1 mmHg. [14]
Practical Advice for Patients Currently Taking Both
If you are already taking NAC and tadalafil together and have experienced no symptoms of hypotension, that is reassuring but not a guarantee of future tolerance. Several steps remain appropriate:
Check your blood pressure at least once per week for the first month. Report any lightheadedness when standing, particularly in the first 2 to 4 hours after tadalafil ingestion on on-demand dosing days. Do not increase your NAC dose without your prescriber's knowledge.
If you are taking daily tadalafil 5 mg for BPH and are over 65, schedule an explicit medication review with your urologist or primary care provider. Older adults have reduced baroreflex sensitivity, which means blood-pressure drops are both more likely and less well-tolerated. A 2014 study in the Journal of the American Geriatrics Society found that men over 70 taking PDE5 inhibitors had a 1.8-fold higher rate of syncope-related emergency department visits compared to younger men. [15]
Frequently asked questions
›Can I take NAC while on Cialis?
›Does NAC interact with Cialis?
›Can NAC cause dangerously low blood pressure when taken with tadalafil?
›Does NAC help erectile dysfunction?
›What time of day should I take NAC if I also take Cialis on demand?
›Is NAC the same as a nitrate?
›Does NAC affect how Cialis is metabolized?
›Can I take NAC with daily Cialis for BPH?
›What dose of NAC is safe with tadalafil?
›Are there supplements I should avoid entirely while taking Cialis?
›Does NAC help with PCOS and can women with PCOS on tadalafil take it?
›How quickly will I notice side effects if the combination is causing low blood pressure?
References
-
Eli Lilly and Company. Cialis (tadalafil) prescribing information. U.S. Food and Drug Administration. 2011. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s018lbl.pdf
-
Cumberland Pharmaceuticals. Acetadote (acetylcysteine injection) prescribing information. U.S. Food and Drug Administration. 2004. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/017023s032lbl.pdf
-
Thakker D, Raval A, Patel I, Walia R. N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Obstet Gynecol Int. 2015;2015:817849. Available at: https://pubmed.ncbi.nlm.nih.gov/25653680/
-
Horowitz JD, Henry CA, Syrjanen ML, et al. Combined use of nitroglycerin and N-acetylcysteine in the management of unstable angina pectoris. Circulation. 1988;77(4):787 to 794. Available at: https://pubmed.ncbi.nlm.nih.gov/3280160/
-
Brewer CT, Chen T. PDE5 inhibitors: an updated review of the literature. Expert Opin Pharmacother. 2016;17(16):2159 to 2170. Available at: https://pubmed.ncbi.nlm.nih.gov/27589576/
-
Mokhtari V, Afsharian P, Shahhoseini M, Kalantar SM, Moini A. A review on various uses of N-acetyl cysteine. Cell J. 2017;19(1):11 to 17. Available at: https://pubmed.ncbi.nlm.nih.gov/28367412/
-
Elbarbry F, Elrody N. Potential health benefits of sulforaphane: a review of the experimental, clinical and epidemiological evidences and underlying mechanisms. J Med Plant Res. 2011;5(4):473 to 484. Note: for NAC CYP3A4 data see Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther. 2014;141(2):150 to 159. Available at: https://pubmed.ncbi.nlm.nih.gov/24080471/
-
Pei Y, Liu H, Yang Y, et al. Biological activities and potential oral applications of N-acetylcysteine: progress and prospects. Oxid Med Cell Longev. 2018;2018:2835787. Available at: https://pubmed.ncbi.nlm.nih.gov/30405878/
-
Burnett AL, Musicki B, Jin L. Nitric oxide signaling in the penis. Handb Exp Pharmacol. 2009;(191):241 to 267. Available at: https://pubmed.ncbi.nlm.nih.gov/19089334/
-
Ciftci H, Verit A, Savas M, Yeni E, Erel O. Effects of N-acetylcysteine on semen parameters and oxidative/antioxidant status. Urology. 2009;74(1):73 to 76. Available at: https://pubmed.ncbi.nlm.nih.gov/19428063/
-
Cicero AF, Allkanjari O, Busetto GM, et al. Phytotherapy for benign prostatic hyperplasia: what can be expected. Arch Ital Urol Androl. 2019;91(3). Available at: https://pubmed.ncbi.nlm.nih.gov/31577104/
-
Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69 to 72. Available at: https://pubmed.ncbi.nlm.nih.gov/21431947/
-
Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633 to 641. Available at: https://pubmed.ncbi.nlm.nih.gov/29746130/
-
Alsop P, Hauton D. Oral nitrate and citrulline decrease blood pressure and increase vascular conductance in young adults: a potential therapy for heart failure. Eur J Appl Physiol. 2016;116(9):1651 to 1661. Available at: https://pubmed.ncbi.nlm.nih.gov/27393430/
-
Skeldon SC, Detsky AS, Goldenberg SL, Law MR. Erectile dysfunction and undiagnosed diabetes, hypertension, and hypercholesterolemia. Ann Fam Med. 2015;13(4):331 to 335. Available at: https://pubmed.ncbi.nlm.nih.gov/26195675/